FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

49 letters match. Newest first.

  1. Neogen Corporation

    FDA found Neogen's HYCOAT animal drug contaminated and made under insanitary conditions after horse deaths.

    High risk
  2. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  3. Safrel Pharmaceuticals LLC

    FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.

    High risk
  4. Lico Industries, LLC., d.b.a. American Towelette Company

    FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.

    High risk
  5. Sante Manufacturing Inc.

    Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.

    High risk
  6. Laboratorios Dr. Collado S.A.

    FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.

    High risk
  7. Revlon Group Holdings, LLC

    FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.

    High risk
  8. GC America, Inc.

    FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.

    High risk
  9. Integrity Partners Group

    FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.

    High risk
  10. Private Label Skin Care, Inc.

    FDA warned Private Label Skin Care about poor quality oversight, continued sale of impurity-affected over-the-counter drugs, and missing drug listings.

    High risk
  11. Sklar Personal Care Inc.

    Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.

    High risk
  12. Rhyz Analytical Labs

    FDA warned Rhyz Analytical Labs, a contract drug testing lab, that inadequate microbial failure investigations and quality oversight made tested drugs adulterated.

    High risk
  13. Chromatography Institute of America dba Compounder’s International Analytical Laboratory

    FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.

    High risk
  14. CCIC Huatongwei International Inspection Co., Ltd.

    FDA warns CCIC Huatongwei after inspection found copied data and missing records in medical device safety tests.

    High risk
  15. Gussyup LLC dba Private Label Grooming

    FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.

    High risk
  16. Healwell Homeo Private Limited

    FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.

    High risk
  17. Neva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi

    FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.

    High risk
  18. Zhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.

    FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.

    High risk
  19. Analytical Food Laboratories, Inc.

    FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.

    High risk
  20. Omni Lens Pvt. Ltd.

    FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.

    High risk
  21. Wittman Pharma, Inc.

    FDA warns Wittman Pharma, an OTC drug maker in Brooksville, Florida, that weak quality oversight and contaminated water make its products adulterated.

    High risk
  22. Greco Gas, Inc.

    Greco Gas, Inc. released medical gases without identity or purity testing and without quality oversight.

    High risk
  23. ARG Laboratories, Inc.

    FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.

    High risk
  24. Optikem International Inc.

    FDA warns Optikem International after inspection found inadequate aseptic controls for sterile ophthalmic drugs, including contamination and validation failures.

    High risk
  25. Sani-Care Salon Products, Inc.

    FDA warns Sani-Care Salon Products over CGMP failures in hand sanitizer manufacturing, including inadequate quality oversight and testing.

    High risk
  26. Cohere Beauty

    FDA cites Cohere Beauty for unvalidated OTC drug manufacturing and inadequate quality oversight at its Santa Fe Springs facility.

    Medium
  27. Master Paints & Chemicals Corp.

    FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.

    High risk
  28. Higley Industries, Inc.

    FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.

    High risk
  29. Bell International Laboratories, Inc.

    Bell International Laboratories, an OTC drugmaker, was cited for manufacturing rule violations including missing glycerin DEG/EG testing and inadequate quality oversight.

    High risk
  30. LightEyez Limited

    LightEyez eye drops sold in the U.S. were contaminated with microbes, and FDA cited unapproved new drug claims for its eye drops.

    High risk
  31. Sichuan Deebio Pharmaceutical Co. Ltd.

    FDA warns Sichuan Deebio Pharmaceutical over API manufacturing and data-integrity failures.

    High risk
  32. Prime Lab LLC

    Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.

    High risk
  33. Inopak, Ltd.

    Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.

    High risk
  34. National Chemical Laboratories

    National Chemical Laboratories’ OTC topical drugs were adulterated after FDA found manufacturing quality violations, including untested BZK and weak quality oversight.

    High risk
  35. Elemental Herbs Inc. d/b/a ALL good

    Elemental Herbs (ALL good) cited for CGMP failures and unapproved, misbranded Goop Skin Recovery Balm.

    High risk
  36. Handock Cosmetics Co., Ltd.

    FDA warns Handock Cosmetics over manufacturing quality failures and unapproved/mislabeled hand sanitizers from South Korea.

    High risk
  37. LCC Ltd.

    LCC Ltd., an OTC drug maker, lacked identity testing for risky ingredients and adequate quality oversight, FDA says.

    High risk
  38. Suhan Aerosol

    Suhan Aerosol, an Indian OTC drug maker, failed to test high-risk ingredients for toxic diethylene/ethylene glycol and lacked quality oversight.

    High risk
  39. Fuller Industries Inc.

    FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.

    High risk
  40. Drivergent, Inc.

    Drivergent's hand sanitizers had acetaldehyde and acetal above allowed limits, FDA says.

    High risk
  41. Cosmetic Science Laboratories LLC

    FDA warned Cosmetic Science Laboratories about OTC sunscreen drugs made without required manufacturing controls.

    High risk
  42. Auto-Chlor System LLC

    Auto-Chlor System LLC made hand sanitizer under poor manufacturing practices and sold it as an unapproved, misbranded new drug.

    High risk
  43. Eksa Mills S.A. de C.V.

    FDA cited Eksa Mills for CGMP violations, including shared-equipment contamination risks, after an April 2022 inspection of its Mexican drug facility.

    High risk
  44. Bi-Coastal Pharma International

    FDA warned Bi-Coastal Pharma International about adulterated drugs due to poor complaint handling, quality-unit oversight, batch release, and training.

    High risk
  45. Colorful Products Corporation

    FDA warned Colorful Products Corporation about serious current good manufacturing practice (CGMP) failures for its over-the-counter topical drugs and hand sanitizers.

    High risk
  46. Specialty Process Labs LLC

    FDA warned Specialty Process Labs about manufacturing quality failures for thyroid USP active ingredient, including unvalidated processes and data control gaps.

    High risk
  47. Chameleon Beverage Co. Inc. dba Chameleon Sanitizer Corporation

    FDA warned Chameleon Sanitizer Corporation that its hand sanitizer was made under insanitary conditions and violated manufacturing and misbranding rules.

    High risk
  48. Syntec Pharma Corp

    FDA warned Syntec Pharma Corp, an API repackager in Farmingdale, New York, that weak cross-contamination controls and quality oversight made its drugs adulterated.

    High risk
  49. Simex Logistics S.A. de C.V.

    Mexican drugmaker Simex Logistics shipped hand sanitizer labeled 70% alcohol that tested at 51%, FDA says.

    High risk